In addition, findings assessing the molecular landscape of HER2-positive breast cancer patients reported an elevated frequency of PIK3CA mutations (61.5%), but the difference to PIK3CA wild-type was not significant [120]. The gene discussed is ERBB2; the disease is breast carcinoma.